신경내분비암 - 시장 인사이트, 역학, 시장 예측(2036년)

Key Highlights:

• Unlike well-differentiated Neuroendocrine Tumors (NETs), NEC behaves biologically similar to small cell carcinoma and is typically diagnosed at an advanced or metastatic stage. Despite growing disease recognition, therapeutic innovation remains limited, and outcomes remain poor.
• First-line therapy typically consists of platinum-based chemotherapy (cisplatin or carboplatin) combined with etoposide. While initial response rates can be relatively high, responses are often short-lived, with rapid relapse and median Overall Survival (mOS) generally ranging between 8-15 months depending on primary site and stage.
• In localized cases, multimodal treatment, including surgery, chemotherapy, and sometimes radiotherapy, may be considered, but recurrence rates remain high even after aggressive management.
• In 2025, the total incident cases of NEC were ~13,500 cases in the 7MM, which are expected to increase during the forecast period.
• Several companies have advanced gene therapies into clinical trials including Boehringer Ingelheim and Oxford BioTherapeutics (obrixtamig [BI 764532]), Merck and Daiichi Sankyo (gocatamig [MK-6070]), Zai Lab and MediLink Therapeutics (ZL-1310), Phanes Therapeutics (peluntamig [PT217]), Legend Biotech and Novartis (LB2102), Abdera Therapeutics, Amgen (IMDELLTRA), and others.

DelveInsight's "Neuroendocrine Carcinoma Market Insights, Epidemiology, and Market Forecast-2036" report delivers an in-depth understanding of the Neuroendocrine Carcinoma, historical and forecasted epidemiology as well as the Neuroendocrine Carcinoma market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

The Neuroendocrine Carcinoma market report provides current treatment practices, emerging drugs, Neuroendocrine Carcinoma market share of the individual therapies, current and forecasted Neuroendocrine Carcinoma market Size from 2022 to 2036 segmented by seven major markets. The Report also covers current Neuroendocrine Carcinoma treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate the best of the opportunities and assesses the underlying potential of the Neuroendocrine Carcinoma market.

Geography Covered:

• The United States
• EU5 (Germany, France, Italy, Spain, and the United Kingdom)
• Japan

Study Period: 2022-2036

Key Factors Driving the Growth of the Neuroendocrine Carcinoma Market

• Rising NEC Incidence: The global increase in diagnosed cases of neuroendocrine tumors (including carcinomas) is a major market growth driver. This uptick is driven by better detection and reporting, alongside an aging population more susceptible to cancer.
• Biomarker-Driven Approaches in Modern Oncology: Advances in molecular profiling have identified recurrent alterations such as TP53 and RB1 loss, as well as potential DNA repair pathway vulnerabilities. This growing biological understanding provides a scientific rationale for exploring targeted therapies and biomarker-driven approaches.
• Role of Platinum-Based Chemotherapy in Advanced NEC: Platinum-based chemotherapy (cisplatin or carboplatin plus etoposide) remains an established global standard of care, producing relatively high objective response rates in newly diagnosed advanced NEC.
• Next-Generation Approaches in Targeted Cancer Therapy: Therapeutic strategies targeting DLL3, antibody-drug conjugates, bispecific T-cell engagers, and other tumor-specific markers may offer new mechanisms beyond cytotoxic chemotherapy.
• Actionable Genomic Subsets in Oncology: Broader implementation of genomic testing may identify actionable subsets, including MSI-high tumors, high tumor mutational burden, NTRK fusions, or DNA repair deficiencies. Even if rare, these subsets offer potential for durable responses with targeted therapies.
• Launch of Emerging Therapies: The dynamics of the NECs market are expected to change in the coming years due to the launch of emerging therapies such as obrixtamig (BI 764532) (Boehringer Ingelheim and Oxford BioTherapeutics), gocatamig (MK-6070) (Merck and Daiichi Sankyo), ZL-1310 (Zai Lab and MediLink Therapeutics), peluntamig (PT217) (Phanes Therapeutics), LB2102 (Legend Biotech and Novartis), ABD147 (Abdera Therapeutics), IMDELLTRA (tarlatamab) (Amgen), and others.

Neuroendocrine Carcinoma Disease Understanding and Treatment Algorithm

Neuroendocrine carcinoma is an aggressive type of cancer that arises from neuroendocrine cells, specialized cells found throughout the body that have characteristics of both nerve cells and hormone-producing endocrine cells. These tumors can develop in many organs, most commonly in the lungs, gastrointestinal tract, and pancreas. Unlike slower-growing neuroendocrine tumors, neuroendocrine carcinomas tend to grow and spread rapidly, often requiring prompt diagnosis and intensive treatment such as chemotherapy, radiation, or targeted therapies. Because their symptoms can be vague or mimic other conditions, early detection can be challenging, making awareness and timely medical evaluation especially important.

Neuroendocrine Carcinoma Diagnosis

Neuroendocrine carcinoma (NEC) diagnosis involves a combination of biochemical blood/urine tests, advanced imaging (CT, MRI, PET scans), and tissue biopsy to determine tumour location, grade, and hormone production. Key biomarkers include Chromogranin A and 5-HIAA. Specialized PET scans (Gallium-68 dotatate) are highly effective in identifying these tumors.

Neuroendocrine Carcinoma Treatment

Treatment for NECs depends on the cancer's site, type (small cell, large cell, or mixed), stage, and overall health. Early-stage large cell NEC in the lung is often treated with surgery followed by chemotherapy and sometimes radiotherapy, while advanced disease typically requires chemotherapy (e.g., etoposide with cisplatin or carboplatin), similar to SCLC, where chemotherapy, often with immunotherapy (atezolizumab or durvalumab), is the mainstay. Digestive NECs may be treated with surgery when localized, combined with chemotherapy given before or after surgery, or with chemoradiotherapy if unresectable, using drugs such as cisplatin, carboplatin, etoposide, or irinotecan. For Mixed neuroendocrine-non-NEN (MiNEN), treatment often involves surgery followed by chemotherapy tailored to the cancer components.

Neuroendocrine Carcinoma Epidemiology

The Neuroendocrine Carcinoma epidemiology section provides insights about the historical and current Neuroendocrine Carcinoma patient pool and forecasted trends for individual seven major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the Neuroendocrine Carcinoma market report also provides the diagnosed patient pool and their trends along with assumptions undertaken.

Key Findings

The disease epidemiology covered in the report provides historical as well as forecasted Neuroendocrine Carcinoma epidemiology scenario in the 7MM covering the United States, EU5 countries (Germany, Spain, Italy, France, and the United Kingdom), and Japan from 2022 to 2036.

• In 2025, the total incident cases of NEC were ~13,500 cases in the 7MM, which are expected to increase during the forecast period.
• In 2025, Japan had the least number of NEC cases i.e., 650 cases while the US had the highest number of cases i.e., nearly 8,900 cases.
• In 2025, the incident cases of large cell NEC were nearly 7,400 in the US.
• In EU4 and the UK, Germany contributes approximately 26% of large cell NEC cases followed by the UK with 22% cases in the total cases.

Neuroendocrine Carcinoma Drug Chapters

The drug chapter segment of the Neuroendocrine Carcinoma report encloses the detailed analysis of Neuroendocrine Carcinoma marketed drugs and late-stage (Phase-III and Phase-II) Neuroendocrine Carcinoma pipeline drugs. It also helps to understand the Neuroendocrine Carcinoma clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug and the latest news and press releases.

Neuroendocrine Carcinoma Emerging Drugs

Obrixtamig (BI 764532): Boehringer Ingelheim and Oxford BioTherapeutics

BI 764532 is an investigational DLL3/CD3 IgG-like T-cell engager for potential treatment of patients with LCNEC that is being developed by Boehringer Ingelheim. The discovery of BI 764532 (OBT620) stemmed from a 2013 partnership combining Oxford BioTherapeutics' OGAP platform for DLL3 antigen identification with Boehringer Ingelheim's oncology and biotherapeutics expertise. Obrixtamig (BI 764532) is being evaluated in this patient population in the ongoing Phase II DAREON-5 trial (NCT05882058).

Gocatamig (MK-6070): Merck and Daiichi Sankyo

MK-6070 is an investigational DLL3-directed tri-specific T-cell engager which is currently being evaluated in the Phase I/II clinical trial for patients with NEPC. In Aug 2024, Daiichi Sankyo and Merck expanded their Antibody Drug Conjugate (ADC) partnership to include MK-6070, with joint global development/commercialization (Merck retaining Japan rights and manufacturing responsibilities).

ZL-1310: Zai Lab and MedLink Therapeutics

ZL-1310 comprises a humanized anti-DLL3 monoclonal antibody connected via a cleavable linker to a novel camptothecin derivative (a topoisomerase one inhibitor) as its payload. The compound was designed with a novel ADC technology platform called TMALIN, which leverages the tumor microenvironment to overcome challenges associated with first-generation ADC therapies. Zai lab initiated the Phase I/II for solid tumors including NECs in May 2025.

Recent Developments in the Neuroendocrine Carcinoma Market

• In October 2025, Boehringer Ingelheim presented the data from the Phase II DAREON-5 trial of obrixtamig in patients with relapsed/refractory DLL3 -high expressing EP-NEC at the European Society for Medical Oncology (ESMO) 2025.
• In June 2025, Legend Biotech presented the Phase I dose-escalating study of LB2102 at the American Society of Clinical Oncology (ASCO) 2025, which demonstrated no Dose Limiting Toxicities (DLTs), and a preliminary efficacy signal was observed up to four dose levels in patients with relapsed or refractory SCLC and LCNEC.

Neuroendocrine Carcinoma Market Outlook

NECs are highly aggressive, poorly differentiated malignancies with a poor prognosis. Chemotherapy remains the first-line standard, yet outcomes are limited, with a mOS of 11-12 months in metastatic disease.

Etoposide + Cisplatin (EP) or Carboplatin (EC) is the established first-line regimen for advanced or unresectable NECs. The NORDIC NEC study reported an ORR of 31% and an mPFS of 4 months. Irinotecan + cisplatin has shown comparable efficacy in Gastro-intestinal NECs (GI-NECs), while the Phase II NABNEC trial demonstrated higher ORR (53% vs 42%) and improved 24-month OS (25% vs 17%) with nab-paclitaxel plus carboplatin vs EP/EC.

There is no standard second-line therapy, and evidence remains limited. FOLFOX or FOLFIRI is commonly used, achieving an Objective Response Rate (ORR) of ~30% and median Progression-free Survival (mPFS) of ~4 months, with no added benefit observed from bevacizumab in the PRODIGE 41-BEVANCE study.

Although NECs exhibit higher PD-L1 expression and TMB compared with NETs, immunotherapy has shown modest benefit. Immune Checkpoint Inhibitors (ICIs) monotherapy yields a Disease Control Rate (DCR) of 20.7-32% and mOS of 4.2 months. Dual ICI therapy has produced higher response rates (ORR 44% in DART), but PFS remains short (≈4 months), and outcomes in platinum-refractory settings are limited (mPFS 1.9 months in NIPINEC).

Combination strategies have also shown constrained efficacy. Nivolumab plus EP achieved an mPFS of 5.7 months (NICE-NEC), while pembrolizumab combinations in second-line settings reported low activity (ORR 5%, mPFS 2 months). Emerging combinations such as surufatinib + toripalimab have demonstrated moderate activity (ORR 23.8%, mPFS ~4 months) post-first-line progression.

Neuroendocrine Carcinoma Drugs Uptake

This section focuses on the rate of uptake of the potential Neuroendocrine Carcinoma drugs recently launched in the Neuroendocrine Carcinoma market or expected to get launched in the market during the study period 2022-2036. The analysis covers Neuroendocrine Carcinoma market uptake by drugs; patient uptake by therapies; and sales of each drug.

Neuroendocrine Carcinoma Drugs Uptake helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs, and allow the comparison of the drugs on the basis of Neuroendocrine Carcinoma market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.

Neuroendocrine Carcinoma Pipeline Development Activities

The Neuroendocrine Carcinoma report provides insights into different therapeutic candidates in Phase II, and Phase III stage. It also analyses Neuroendocrine Carcinoma key players involved in developing targeted therapeutics.

Pipeline Development Activities

The Neuroendocrine Carcinoma report covers the detailed information of collaborations, acquisition, and merger, licensing, patent details, and other information for Neuroendocrine Carcinoma emerging therapies.

Reimbursement Scenario in Neuroendocrine Carcinoma

Approaching reimbursement proactively can have a positive impact both during the late stages of product development and well after product launch. In a report, we take reimbursement into consideration to identify economically attractive indications and market opportunities. When working with finite resources, the ability to select the markets with the fewest reimbursement barriers can be a critical business and price strategy.

KOL- Views

To keep up with current Neuroendocrine Carcinoma market trends, we take KOLs and SMEs ' opinion working in the Neuroendocrine Carcinoma domain through primary research to fill the data gaps and validate our secondary research. Their opinion helps to understand and validate current and emerging therapies treatment patterns or Neuroendocrine Carcinoma market trends. This will support the clients in potential upcoming novel treatment by identifying the overall scenario of the market and the unmet needs.

Competitive Intelligence Analysis

We perform Competitive and Market Intelligence analysis of the Neuroendocrine Carcinoma Market by using various Competitive Intelligence tools that include - SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies etc. The inclusion of the analysis entirely depends upon the data availability.

Scope of the Report:

• The report covers the descriptive overview of Neuroendocrine Carcinoma, explaining its causes, signs and symptoms, pathophysiology, diagnosis and currently available therapies
• Comprehensive insight has been provided into the Neuroendocrine Carcinoma epidemiology and treatment in the 7MM
• Additionally, an all-inclusive account of both the current and emerging therapies for Neuroendocrine Carcinoma is provided, along with the assessment of new therapies, which will have an impact on the current treatment landscape
• A detailed review of the Neuroendocrine Carcinoma market; historical and forecasted is included in the report, covering drug outreach in the 7MM
• The report provides an edge while developing business strategies, by understanding trends shaping and driving the global Neuroendocrine Carcinoma market

Report Highlights:

• In the coming years, the Neuroendocrine Carcinoma market is set to change due to the rising awareness of the disease, and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market
• The companies and academics are working to assess challenges and seek opportunities that could influence Neuroendocrine Carcinoma R&D. The therapies under development are focused on novel approaches to treat/improve the disease condition
• Major players are involved in developing therapies for Neuroendocrine Carcinoma. The launch of emerging therapies will significantly impact the Neuroendocrine Carcinoma market
• A better understanding of disease pathogenesis will also contribute to the development of novel therapeutics for Neuroendocrine Carcinoma
• Our in-depth analysis of the pipeline assets across different stages of development (Phase III and Phase II), different emerging trends and comparative analysis of pipeline products with detailed clinical profiles, key cross-competition, launch date along with product development activities will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the research and development activities

Neuroendocrine Carcinoma Report Insights

• Neuroendocrine Carcinoma Patient Population
• Therapeutic Approaches
• Neuroendocrine Carcinoma Pipeline Analysis
• Neuroendocrine Carcinoma Market Size and Trends
• Neuroendocrine Carcinoma Market Opportunities
• Impact of upcoming Neuroendocrine Carcinoma Therapies

Neuroendocrine Carcinoma Report Key Strengths

• 11 Years Forecast
• 7MM Coverage
• Neuroendocrine Carcinoma Epidemiology Segmentation
• Key Cross Competition
• Highly Analyzed Market
• Drugs Uptake

Neuroendocrine Carcinoma Report Assessment

• Current Treatment Practices
• Unmet Needs
• Neuroendocrine Carcinoma Pipeline Product Profiles
• Neuroendocrine Carcinoma Market Attractiveness
• Market Drivers and Barriers

Key Questions:

Market Insights:

• What was the Neuroendocrine Carcinoma drug class share (%) distribution in 2022 and how it would look like in 2036?
• What would be the Neuroendocrine Carcinoma total market size as well as market size by therapies across the 7MM during the study period (2022-2036)?
• What are the key findings pertaining to the market across 7MM and which country will have the largest Neuroendocrine Carcinoma market size during the study period (2022-2036)?
• At what CAGR, the Neuroendocrine Carcinoma market is expected to grow by 7MM during the study period (2022-2036)?
• What would be the Neuroendocrine Carcinoma market outlook across the 7MM during the study period (2022-2036)?
• What would be the Neuroendocrine Carcinoma market growth till 2036, and what will be the resultant market Size in the year 2036?
• How would the unmet needs affect the market dynamics and subsequent analysis of the associated trends?

Epidemiology Insights:

• What are the disease risk, burden, and regional/ethnic differences of the Neuroendocrine Carcinoma?
• What are the key factors driving the epidemiology trend for seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan?
• What is the historical Neuroendocrine Carcinoma patient pool in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan?
• What would be the forecasted patient pool of Neuroendocrine Carcinoma in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan?
• Where will be the growth opportunities in the 7MM with respect to the patient population pertaining to Neuroendocrine Carcinoma?
• Out of all 7MM countries, which country would have the highest prevalent population of Neuroendocrine Carcinoma during the study period (2022-2036)?
• At what CAGR the patient population is expected to grow in 7MM during the study period (2022-2036)?

Current Treatment Scenario, Marketed Drugs and Emerging Therapies:

• What are the current options for the Neuroendocrine Carcinoma treatment in addition to the approved therapies?
• What are the current treatment guidelines for the treatment of Neuroendocrine Carcinoma in the USA, Europe, and Japan?
• What are the Neuroendocrine Carcinoma marketed drugs and their respective MOA, regulatory milestones, product development activities, advantages, disadvantages, safety and efficacy, etc.?
• How many companies are developing therapies for the treatment of Neuroendocrine Carcinoma?
• How many therapies are in-development by each company for Neuroendocrine Carcinoma treatment?
• How many are emerging therapies in mid-stage, and late stage of development for Neuroendocrine Carcinoma treatment?
• What are the key collaborations (Industry - Industry, Industry - Academia), Mergers and acquisitions, licensing activities related to the Neuroendocrine Carcinoma therapies?
• What are the recent novel therapies, targets, mechanisms of action and technologies being developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Neuroendocrine Carcinoma and their status?
• What are the current challenges faced in drug development?
• What are the key designations that have been granted for the emerging therapies for Neuroendocrine Carcinoma?
• What are the global historical and forecasted market of Neuroendocrine Carcinoma?

Reasons to buy:

• The report will help in developing business strategies by understanding trends shaping and driving the Neuroendocrine Carcinoma market
• To understand the future market competition in the Neuroendocrine Carcinoma market and Insightful review of the key market drivers and barriers
• Organize sales and marketing efforts by identifying the best opportunities for Neuroendocrine Carcinoma in the US, Europe (Germany, Spain, Italy, France, and the United Kingdom) and Japan
• Identification of strong upcoming players in the market will help in devising strategies that will help in getting ahead of competitors
• Organize sales and marketing efforts by identifying the best opportunities for Neuroendocrine Carcinoma market
• To understand the future market competition in the Neuroendocrine Carcinoma market

Table of Contents

1. Key Insights

2. Executive Summary of Neuroendocrine Carcinoma

3. Competitive Intelligence Analysis for Neuroendocrine Carcinoma

4. Neuroendocrine Carcinoma: Market Overview at a Glance

• 4.1. Neuroendocrine Carcinoma Total Market Share (%) Distribution in 2022
• 4.2. Neuroendocrine Carcinoma Total Market Share (%) Distribution in 2036

5. Neuroendocrine Carcinoma: Disease Background and Overview

• 5.1. Introduction
• 5.2. Sign and Symptoms
• 5.3. Pathophysiology
• 5.4. Risk Factors
• 5.5. Diagnosis

6. Patient Journey

7. Neuroendocrine Carcinoma Epidemiology and Patient Population

• 7.1. Epidemiology Key Findings
• 7.2. Assumptions and Rationale: 7MM
• 7.3. Epidemiology Scenario: 7MM
  • 7.3.1. Neuroendocrine Carcinoma Epidemiology Scenario in the 7MM (2022-2036)
• 7.4. United States Epidemiology
  • 7.4.1. Neuroendocrine Carcinoma Epidemiology Scenario in the United States (2022-2036)
• 7.5. EU-5 Country-wise Epidemiology
  • 7.5.1. Germany Epidemiology
    • 7.5.1.1. Neuroendocrine Carcinoma Epidemiology Scenario in Germany (2022-2036)
  • 7.5.2. France Epidemiology
    • 7.5.2.1. Neuroendocrine Carcinoma Epidemiology Scenario in France (2022-2036)
  • 7.5.3. Italy Epidemiology
    • 7.5.3.1. Neuroendocrine Carcinoma Epidemiology Scenario in Italy (2022-2036)
  • 7.5.4. Spain Epidemiology
    • 7.5.4.1. Neuroendocrine Carcinoma Epidemiology Scenario in Spain (2022-2036)
  • 7.5.5. United Kingdom Epidemiology
    • 7.5.5.1. Neuroendocrine Carcinoma Epidemiology Scenario in the United Kingdom (2022-2036)
  • 7.5.6. Japan Epidemiology
    • 7.5.6.1. Neuroendocrine Carcinoma Epidemiology Scenario in Japan (2022-2036)

8. Treatment Algorithm, Current Treatment, and Medical Practices

• 8.1. Neuroendocrine Carcinoma Treatment and Management
• 8.2. Neuroendocrine Carcinoma Treatment Algorithm

9. Neuroendocrine Carcinoma Unmet Needs

10. Key Endpoints of Neuroendocrine Carcinoma Treatment

11. Neuroendocrine Carcinoma Marketed Products

• 11.1. List of Neuroendocrine Carcinoma Marketed Drugs in the 7MM
• 11.2. Drug Name: Company Name
  • 11.2.1. Product Description
  • 11.2.2. Regulatory Milestones
  • 11.2.3. Other Developmental Activities
  • 11.2.4. Pivotal Clinical Trials
  • 11.2.5. Summary of Pivotal Clinical Trial

12. Neuroendocrine Carcinoma Emerging Therapies

• 12.1. Key Cross
• 12.2. Drug Name: Company Name
  • 12.2.1. Product Description
  • 12.2.2. Other Developmental Activities
  • 12.2.3. Clinical Development
  • 12.2.4. Safety and Efficacy
  • 12.2.5. Product Profile

13. Neuroendocrine Carcinoma: Seven Major Market Analysis

• 13.1. Key Findings
• 13.2. Neuroendocrine Carcinoma Market Size in 7MM
• 13.3. Neuroendocrine Carcinoma Market Size by Therapies in the 7MM

14. Attribute analysis

15. 7MM: Market Outlook

• 15.1. United States: Market Size
  • 15.1.1. Neuroendocrine Carcinoma Total Market Size in the United States
  • 15.1.2. Neuroendocrine Carcinoma Market Size by Therapies in the United States
• 15.2. EU-5 countries: Market Size and Outlook
• 15.3. Germany Market Size
  • 15.3.1. Neuroendocrine Carcinoma Total Market Size in Germany
  • 15.3.2. Neuroendocrine Carcinoma Market Size by Therapies in Germany
• 15.4. France Market Size
  • 15.4.1. Neuroendocrine Carcinoma Total Market Size in France
  • 15.4.2. Neuroendocrine Carcinoma Market Size by Therapies in France
• 15.5. Italy Market Size
  • 15.5.1. Neuroendocrine Carcinoma Total Market Size in Italy
  • 15.5.2. Neuroendocrine Carcinoma Market Size by Therapies in Italy
• 15.6. Spain Market Size
  • 15.6.1. Neuroendocrine Carcinoma Total Market Size in Spain
  • 15.6.2. Neuroendocrine Carcinoma Market Size by Therapies in Spain
• 15.7. United Kingdom Market Size
  • 15.7.1. Neuroendocrine Carcinoma Total Market Size in the United Kingdom
  • 15.7.2. Neuroendocrine Carcinoma Market Size by Therapies in the United Kingdom
• 15.8. Japan Market Outlook
  • 15.8.1. Japan Market Size
  • 15.8.2. Neuroendocrine Carcinoma Total Market Size in Japan
  • 15.8.3. Neuroendocrine Carcinoma Market Size by Therapies in Japan

16. Access and Reimbursement Overview of Neuroendocrine Carcinoma

17. KOL Views

18. Market Drivers

19. Market Barriers

20. Appendix

• 20.1. Bibliography
• 20.2. Report Methodology

21. DelveInsight Capabilities

22. Disclaimer

23. About DelveInsight

The table of contents is not exhaustive; the final content may vary.